■ Market Review

On Oct. 24, Ilyang Pharmaceutical (007570) declined 2.71% to 41,350 won (US$ 36.49). It had declined 16.21% through the past month. Standard deviation, which indicates volatility of stock, records 2.5% over the same period over one month.

Compared with its close competitors within the same industry, KOSPI, even though the monthly earnings rate of Ilyang Pharmaceutical recorded negative, its volatility for 1 month was proper. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -6.4%. In spite of stock price decline, the return-on-risk remained around the average of its peer group. However, compared with the KOSPI industry, the return-on-risk is below the industrial mean, -0.5, and thus it is hard to say that the industrial comparison performance was positive.

■ Earnings & Valuation

ILYANG PHARM(007570): 2Q(Apr ~ June) of 2016 Earnings (reported at July 26. 2016)

Compared with 4 close competitors with similar market capitalization within its industry, ILYANG PHARM's P/B ratio, a financial ratio of a company's book value, and its P/E ratio, a price-paid ratio of annual net income, are both at a relatively higher level.

Close Compatitors ROE

■ Investor Group

Cumulated shareholdings per investor group (1Mo)  

* Other Investor groups, included as "other corporations", are considered as "Individuals".